Kourtney White, PA
Medical · Douglas, WYNPI 1184212441
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $534 and has fallen 84.7% since, to $82 in 2025.
Across 57 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$208
- GSK$152
- Lilly USA, LLC$146
- Novo Nordisk$83
- AstraZeneca$82
- E.r. Squibb & Sons, L.L.C.$68
- plus $393 from 10 others
What the payments were for
- Food & beverage$1,132100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $208 |
| GSK | 9 | $152 |
| Lilly USA, LLC | 9 | $146 |
| Novo Nordisk | 5 | $83 |
| AstraZeneca | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $68 |
| Merck | 4 | $68 |
| Medtronic | 2 | $67 |
| Insulet Corporation | 1 | $50 |
| Organon | 3 | $46 |
| Tandem Diabetes Care, Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $40 |
| Dexcom, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
How this compares
$1,132 in reported general payments places this provider in the 65th percentile of 56 medical providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $54,283 |
| JardianceEmpagliflozin | 50 | $53,344 |
| MounjaroTirzepatide | 26 | $32,634 |
| TrulicityDulaglutide | 25 | $28,239 |
| FarxigaDapagliflozin Propanediol | 27 | $27,380 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $17,095 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $14,976 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $14,364 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,414 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $7,693 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $4,954 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,554 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $3,117 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 20 | $2,899 |
| Ultra-Fine Original Pen NeedlePen Needle, Diabetic | 20 | $1,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $146 | $60,87351 claims |
| Novo NordiskOzempic | $83 | $54,28358 claims |
| AstraZenecaFarxiga | $82 | $27,38027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 medical providers in Wyoming.
Other medical in Douglas
- Allison BarnettDouglas$488
- Oscar AguirreDouglas$19
- Jessica NeauSheridan$7K
- Autumn BarrettSheridan$6K
- Mark SandersRock Springs$5K
- John VippermanCody$5K
- Gary OttersbachCasper$4K
- Sharae InmanSheridan$4K
- Jennifer RosicsCasper$3K
- Melissa JewellRock Springs$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.